

Contents

Acknowledgements.....	vii
Contents.....	ix
Table of Figure.....	xiii
List of Table.....	xxi
List of Schemes.....	xxiii
Abbreviations.....	xxv
Chapter 1: Introduction and Literature Review	1
1.1 Cancer	1
1.2 Traditional methods of treatment and their drawbacks.....	1
1.2.1 Surgery	1
1.2.2 Radiation therapy.....	2
1.2.3 Chemotherapy.....	2
1.3 Barriers and side effects in chemotherapy	2
1.4 Drug delivery in cancer (Need of controlled drug delivery).....	3
1.5 Mechanism of drug release from polymers.....	5
1.5.1 Diffusion Controlled release.....	6
1.5.2 Solvent Controlled release.....	7
1.5.3 Degradation controlled release	7
1.5.4 Stimuli Controlled release	8
1.6 Drug delivery systems.....	8
1.6.1 Liposomes.....	8
1.6.2 Dendrimers	9
1.6.3 Hydrogels	9
1.6.4 Micelle as a drug carrier	10
1.6.5 Polymeric nanoparticles	11
1.7 Bio polymers for controlled drug release.....	12
1.7.1 Chitosan.....	12
1.7.2 Dextrin.....	12
1.7.3 Cellulose.....	13
1.7.4 Pullulan.....	14
1.7.5 Hyaluronan	14
1.7.6 Alginates.....	15

1.7.7	Gelatin	15
1.8	Strategies for polymer modification.....	16
1.8.1	Grafting a versatile method for polymer grafting.....	16
1.8.2	Atom transfer radical polymerization.....	18
1.8.3	Reversible addition-fragmentation chain transfer polymerization	19
1.9	Modes of delivery and cancer treatment	20
1.9.1	Transdermal patches.....	20
1.9.2	Subcutaneous.....	22
1.9.3	Intravenous	23
1.9.4	Photodynamic therapy	24
1.10	Cyclodextrin in drug delivery and cancer treatment	24
1.10.1	Graft copolymers	26
1.10.2	Nanoparticles	27
1.10.3	Dendrimers.....	29
1.10.4	Hydrogels.....	29
1.10.5	Nanofibers.....	30
1.11	Scope and objectives of present work.....	30
1.12	Plan of present work.....	31
Chapter 2:	Experimental Section	35
2.1	Synthesis of different polymeric architectures for controlled drug release	35
2.1.1	Materials.....	35
2.1.2	Synthesis of polyurethane graft CD copolymers.....	35
2.1.3	Synthesis of short chain prepolymer and its grafting on CD.....	37
2.1.4	Synthesis of different generations of CD	38
2.1.5	Synthesis of polyurethane grafted linear (dextrin) brush Copolymers.....	40
2.2	Characterizations.....	41
2.2.1	Proton NMR	41
2.2.2	Fourier transform infrared spectroscopy (FTIR)	41
2.2.3	UV-Vis.....	41
2.2.4	Thermal analysis.....	42
2.2.5	Mechanical responses	42
2.2.6	Swelling and contact angle studies.....	42
2.2.7	Structural analysis.....	43
2.2.8	Morphological investigation.....	43
2.3	In-Vitro Drug release	44
2.4	Biocompatibility.....	44
2.4.1	Cell Culture.....	44

2.4.2	Cell adhesion	45
2.4.3	Fluorescence imaging.....	46
2.5	Animal studies.....	46
2.5.1	In-vivo anti-tumor efficacy.....	46
2.5.2	Histopathology and biochemical assay	47
2.5.3	Biodistribution.....	48
Chapter 3: Efficacy of polyurethane graft on cyclodextrin to control drug release for tumor treatment.....		49
3.1	Introduction.....	49
3.2	Results and discussion	51
3.2.1	Different architecture through grafting	51
3.2.2	Thermal and mechanical responses with structural alteration in graft copolymer	55
3.3	Sustained release of drug using varying architecture.....	60
3.4	Biocompatibility and in-vitro efficiency under controlled release	66
3.5	Efficacy of controlled release for cancer treatment in animal model	70
3.6	Conclusion	78
Chapter 4: Grafted Cyclodextrin as carrier for control drug delivery and efficient cell killing.....		81
4.1	Introduction.....	81
4.2	Results and discussion	82
4.2.1	Spectroscopic evidence for grafting.....	82
4.2.2	Thermal and mechanical responses in graft copolymer	86
4.2.3	In-vitro drug release and polymer drug interaction.....	89
4.3	Biocompatibility and in-vitro toxicity.....	94
4.4	Conclusion	99
Chapter 5: Third Generation Cyclodextrin Graft with Polyurethane Embedded in Hydrogel for a Sustained Drug Release: Complete Shrinkage of Melanoma		101
5.1	Introduction.....	101
5.2	Results and discussion	103
5.2.1	Spectroscopic characterization	103
5.2.2	Structure and Morphology.....	105
5.3	In-vitro drug release	107
5.4	In-vitro cytotoxicity	109

5.5	In Vivo efficiency.....	112
5.6	Conclusion.....	118
Chapter 6: Modified biopolymer dextrin grafted polyurethane copolymer hydrogels for sustained drug release and Melanoma treatment.....		121
6.1	Introduction	121
6.2	Results and discussion.....	123
6.2.1	Spectroscopic evidence of grafting.....	123
6.2.2	Thermal and mechanical responses with structural alteration in brush copolymer 127	
6.2.3	Structural and surface characterization.....	130
6.3	In Vitro drug release from brush polymers/hydrogel.....	132
6.4	Biocompatibility studies.....	137
6.5	Cellular uptake and Cytotoxicity studies	139
6.6	In-Vivo studies on Melanoma model.....	142
6.7	Conclusion.....	149
Chapter 7: Conclusion and Future Scope.....		151
7.1	Conclusion.....	151
7.2	Scope for future work.....	155
References.....		157
List of Publications		176
Book Chapter		178
Patents filed.....		178

Table of Figure

Figure 1.1: A schematic presentation of controlled release systems over traditional release.	4
Figure 1.2: Different polymeric carriers for controlled drug delivery.....	10
Figure 1.3: Schematic representation of different grafting methods.	17
Figure 1.4: Mechanism of ATRP[71].....	18
Figure 1.5: RAFT polymerization mechanism.	20
Figure 1.6: A cooperative system of chemotherapy and photothermal therapy for treatment of A431 tumors by the integration near-infrared responsive GNR-PEG@MNs and MPEG-PDLLA-DTX micelles. (Step 1: Injection of DTX loaded micelles; Step 2: After the injection, pressing of GNR-PEG@MNs at the tumor sites and under 2 W/cm ² irradiation by 808 nm laser within 5 min).	22
Figure 1.7: Structures of cyclodextrin. Top- chemical structure of cyclodextrin, Bottom 3D structure of α , β and γ cyclodextrins with their dimensions.	26
Figure 1.8: a) Schematic presentation of multifunctional MSNPs-CD-PEG-FA for targeted and controlled drug delivery; b) Release profiles of Dox loaded MSNPs-S-S-CD under different pH environment at 37 °C; c) Cell viability of HeLa cells after incubation with free Dox, Dox-MSNPs-CD-PEG-FA, or Dox-MSNPs-CD-PEG at different Dox doses. ...	28
Figure 3.1: a) ¹ H NMR Spectra of CD, PU and their indicated grafts showing new peak position due to grafting marked by ‘a’ and change of hydrogen bonding as presented marked by ‘b’ b)NMR spectra of CD,PU and its respected graft showing appearance of new peak at 1.5 ppm attributed to proton of PTMG. ; c) Gel permeation chromatogram of graft copolymers showing lower elution time for high graft density copolymers d) FTIR spectra of pure CD, PU and their graft copolymers as indicated.....	53
Figure 3.2: a) UV- Vis Spectra of pure and graft copolymers. Vertical lines indicate the peak position for n→ π^* transition of carbonyl peak; and b) Schematic presentation of the architecture of the graft copolymers with varying graft density. It also indicates the type of interaction present in different systems as appeared from coiled to open architecture arise from intramolecular to intermolecular interaction, respectively.	55

Figure 3.3: a) Thermal stability (TGA thermogrammes) of pure CD, PU and their grafts as measured through thermogravimetric analyser; b) DSC thermogrammes of PU and its graft copolymers as indicated both for heating (bottom three) and cooling cycle (top two thermogrammes). The inset figure represents DSC pattern of pristine CD; c) Stress–strain curves of graft copolymers showing elongation at break. 56

Figure 3.4: a) XRD patterns of pure CD, PU and their graft copolymers; b) Small angle neutron scattering profile of PU and its graft copolymers. Inset figures represent the Debye-Bueche fitting of the initial data points showing the correlation length; c) AFM images of CD, PU and their grafts in semi contact mode ($10 \times 10 \mu\text{m}^2$); and d) Optical images of the graft copolymers showing greater agglomerates. 59

Figure 3.5: a) Cumulative release of drug from the indicated specimens showing sustained drug release profile from graft copolymers; b) Schematic model showing the architecture of copolymer and drug which cause sustained release from low graft density copolymer against high graft density copolymer; c) Bar diagram of contact angle of various graft copolymers showing hydrophobic nature of low graft density copolymers as compared to high graft density copolymer. 61

Figure 3.6: Mathematical models for drug release kinetics. (a) Zero order model, (b) First order model, (c) Higuchi model, (d) Korsmeyer- Peppas model..... 63

Figure 3.7: a) UV-Vis spectra of indicated samples showing polymer-drug interaction. Vertical lines indicate the respective peak positions; b) DSC thermogrammes of representative CDgPU-L and its drug loaded specimen showing shifting of melting peak and heat of fusion in presence of drug; c) DSC thermogrammes of pure and drug loaded CD. 65

Figure 3.8: Biological responses of graft copolymers through cellular studies. a) Cell viability of indicated samples at time interval of 1, 3 and 5 days through MTT assay measurement; b) Fluorescence microscopic images of cell cultured on indicated specimens and images are taken after one day of cell proliferation (mag 40 \times); c) Morphology of cells grown on different sample surface as indicated (cell adhesion); d) Quantification of cell adhesion through optical density measurement of adhered cells over various sample surface. 66

Figure 3.9: In vitro cytotoxicity at different drug concentration: a) 10 $\mu\text{g}/\text{ml}$; b) 100 $\mu\text{g}/\text{ml}$ c) 500 $\mu\text{g}/\text{ml}$; d) Fluorescence images after AO/EB staining of cells treated with pure drug and drug loaded graft copolymers as mentioned (500 $\mu\text{g}/\text{ml}$). 69

Figure 3.10: a) Images of mice after tumor generation using B16 F10 cell line and tumor size after treatment with drug loaded indicated systems for varying time interval; b)

Relative changes in tumor volume with time treated with indicated patches; c) Relative body weight percentage change as a function of treatment time..... 72

Figure 3.11: a) Histopathological analysis of organs like liver, kidney, spleen and tumor dissected from mice after 30 days of treatment and b) Biochemical parameters, Hepatic function test including ALT, ALP, AST and renal function namely BUN and Creatinine of the mice treated with indicated patches. The arrows indicate the corresponding values of healthy mice [150]. All the results presented are mean \pm standard deviation (SD) values obtained from three independent experiments, where *P <0.05, **P< 0.01, and ***P <0.001. 73

Figure 3.12: Comparison of efficacy of graft patch vs. conventional graft inject system. a) Images of mice after 15 and 30 days of treatment with patch and injected systems; b) Relative changes in tumor volume with time; c) Relative body weight % of mice treated with graft patch and injection using similar composition; d) Biochemical parameter analysis including AST, ALT, ALP, BUN and CREATININE. The arrows indicate the corresponding values in healthy mice..... 77

Figure 4.1: a) ^1H NMR Spectra of CD, prepolymer (PP) and their indicated grafts. Occurrences of new peak due to grafting are marked as ‘a’ and another peak at $\delta\sim 8$ ppm demarcates the intermolecular hydrogen bonding. Calculation of degree of substitution from integrated peak area is presented in the text; b) FTIR spectra of pure CD, PP and their graft copolymers as indicated; c) UV- Vis spectra of CD and indicated graft copolymers. Vertical lines indicate the peak position for $n\text{-}\pi^*$ transition of carbonyl peak; d) Molecular weight analysis through gel permeation chromatogram of graft copolymers. 83

Figure 4.2: Model showing formation of two different graft density copolymers. 85

Figure 4.3: a) Thermal stability (TGA thermogrammes) of pure CD, PP and their indicated grafts; b) DSC thermograms of PP and its indicated graft copolymers showing melting temperature and heat of fusion..... 87

Figure 4.4: a) Stress–strain curves of graft copolymers under uniaxial stretching showing elongation at break; b) Toughness of indicated graft copolymers; c) Modulus of the graft copolymers; d) XRD patterns of pure CD, PP and their graft copolymers; and e) AFM images of CD, PP and their indicated grafts in semi contact mode ($5\times 5\ \mu\text{m}^2$). 88

Figure 4.5: a) Cumulative release profiles of drug loaded graft copolymers indicated, showing controlled drug release profile from graft copolymers; b) Schematic model showing the drug release from pure CD and graft copolymer. c) Contact angle of graft copolymers and PP showing low graft density copolymers are hydrophobic as compared to high graft density copolymer. 91

Figure 4.6: Mathematical models for drug release kinetics. a) Zero order model, b) First order model, c) Higuchi model, d) Korsmeyer- Peppas model. The correlation coefficients along with other parameters for each model are presented in table below 93

Figure 4.7: a) UV-Vis spectra of drug loaded graft copolymer and CD showing polymer-drug interaction. Vertical lines indicate the respective peak positions; b) DSC thermogrammes of representative CgP-H and its drug loaded sample showing depression of melting peak and heat of fusion in presence of drug. 94

Figure 4.8: Biocompatibility assessment through cellular studies: a) Cell viability of indicated samples at three different time interval through MTT assay measurement of pure CD and indicated graft copolymers; b) Fluorescence microscopic images of cell cultured on indicated grafted copolymers and images are taken after 24 h of incubation (mag 40×); c) Cell adhesion, depicting morphology of the cells over polymer/graft copolymer surfaces; d) Phase contrast images of adhered cells over various indicated sample surfaces; e) In-vitro cytotoxicity of native drug and drug loaded graft copolymers against HeLa cells after 1, 3 and 5 days of incubation time interval; and f) Fluorescence images after AO/EB staining of cells treated with pure drug and indicated drug loaded graft copolymers showing relative number density of cells and their health after treatment as mentioned..... 97

Figure 5.1: a) ^1H NMR Spectra of CD, and their indicated generations showing new peak position due to grafting marked by ‘a’ and ‘b’. b) FTIR spectra of pure CD and its generations and superstructure as indicated showing shifting of peak position arising from interaction; c) Gel permeation chromatograms of generations showing lower elution time for 3G-g-PU w.r.t 2G/3G; and d) UV-Vis spectra of pure CD, its generation and superstructure. Vertical lines indicate the peak position for $n-\pi^*$ transition of carbonyl peak. Inset figure show the UV-vis pattern of pure polyurethane. 104

Figure 5.2: Structural elucidation a) XRD pattern of all the systems showing reduced crystallinity with grafting. b) Small angle neutron scattering and its Debye-Buche fitting model in inset showing an increase in blob size with higher generations due to more interactions. c) TEM images of pure CD and 3G-PU..... 106

Figure 5.3: a) Cumulative release of paclitaxel from CD, indicated generations showing sustained drug release profile from superstructure; b) Schematic model showing location of drug in various vehicles which cause sustained release from 3G-g-PU against fast release in 2G. Drug loaded 3G-g-PU is placed in MC hydrogel; c) DSC thermogrammes of with and without drug loaded 3G-g-PU showing the shift of melting peak and heat of fusion in presence of drug; d) UV-Vis spectra of indicated specimens showing polymer-drug interaction. Vertical lines indicate the respective peak positions..... 108

Figure 5.4: Mathematical models for drug release kinetics a) Korsmeyer- Peppas model, b) First order model, c) Zero order model, d) Higuchi model. 109

Figure 5.5: a) Cell viability of indicated samples at indicated time interval through MTT assay measurement; b) Phase contrast images of cells grown on different indicated sample surfaces (cell adhesion); In-vitro cytotoxicity (cell killing) by pure drug and drug loaded 3G-g-PU against HeLa cells at different doses c) at 20 $\mu\text{g/ml}$, d) at 200 $\mu\text{g/ml}$ as a function of time; and e) Fluorescence images after AO/EB staining of cells treated with pure drug and drug loaded indicated specimens showing differential cell density..... 111

Figure 5.6: a) Images of mice at initial day and after treatment with Mod-Gel-D and Gel-D indicated systems for varying time interval. Black spots indicate the cells/area containing melanin while tumor size is measured from the swollen area of respective mice; b) Relative changes in tumor volume with time treated with indicated Gels and patch; c) Relative changes in body weigh with time treated with indicated Gels and patch; d) Mice showing the formation of hydrogel after subcutaneous injection. 113

Figure 5.7: a) Plasma drug concentration versus time profile for pure drug and Mod-gel-D treated albino mice after intravenous administration at 5 mg/kg body weight and an equivalent amount of drug in Mod-Gel. Biochemical parameters, b) Hepatic function test including AST, ALT, and ALP c) Renal function namely BUN and Creatinine of the mice treated with Gels. Corresponding values of healthy mice are indicated by the arrows; d) Histopathological analysis of organs like liver, kidney, spleen and tumor dissected from mice after 30 days of treatment. Results are presented in mean value $\pm\text{SD}$, $n=5$. *** $p<0.001$, ** $p<0.05$ and * $p<0.01$ 115

Figure 6.1: a) ^1H NMR Spectra of Dex, PU and their indicated grafts showing new peak position due to grafting marked by ‘b’ and change of hydrogen bonding as presented marked by ‘a’. b) ^{13}C NMR Spectra of Dex, PU and their indicated grafts c) FTIR spectra of pure Dex, PU and their graft copolymers as indicated; d) Gel permeation chromatogram of graft copolymers showing lower elution time for high graft density copolymers; and e) Schematic presentation of the architecture of all the graft copolymers with varying graft density..... 125

Figure 6.2: a) Thermal stability (TGA thermogrammes) of pure Dextrin, prepolymer (P) and their grafts D-P-L and D-P-H as measured through thermogravimetric analyzer; b) DSC thermogrammes of P D-P-L and D-P-H as indicated both for heating and cooling cycle (top two thermogrammes). Melting temperature and heat of fusions are mentioned in corresponding colour code. The inset figure represents DSC pattern of pristine Dextrin; c) Stress–strain curves of D-P-L and D-P-H. Inset bar graphs indicate the modulus and toughness of the copolymers..... 128

Figure 6.3: Structural and morphology investigation, a) XRD patterns of pure Dextrin, PU and their graft copolymers; b) Small angle neutron scattering profile of D and P and its graft copolymers. Inset figures represent the Debye-Bueche fitting of the initial data points showing the correlation length; c) Optical images of the graft copolymers showing greater agglomerates. d) AFM images of Dextrin, P and their grafts in semi contact mode ($10 \times 10 \mu\text{m}^2$). 132

Figure 6.4: a) Cumulative release profiles of drug loaded graft copolymers and injectable gel indicated, showing controlled drug release profile from graft copolymers and gel; b) Schematic model showing the drug release from graft copolymer and gel. c) FTIR spectra of pure and drug loaded systems, shifting in peaks indicating interactions d) DSC thermogrammes of pure and drug loaded systems indicating lowering in melting peak along with reduced heat of fusion values..... 135

Figure 6.5: Mathematical models for drug release kinetics a) Korsmeyer- Peppas model, b) First order model, c) Higuchi model d) Zero order model. 137

Figure 6.6: Biological responses of brush polymers through cellular studies. a) Cell viability of indicated samples at time interval of 1, 3 and 5 days through MTT assay measurement; b) Fluorescence microscopic images of cell cultured on indicated specimens and images are taken after one day of cell proliferation (mag 40 \times); c) Quantification of cell adhesion through optical density measurement of adhered cells over various sample surface; d) Morphology of cells grown on different sample surface as indicated (cell adhesion). 139

Figure 6.7: a) Cellular uptake study into HeLa cells after different incubation time. The observed red fluorescence due to rhodamine tagged drug is observed in the Brush Copolymer with higher intensity treated at $100 \mu\text{g mL}^{-1}$; b) Cell viability after treating with $20 \mu\text{g mL}^{-1}$ of drug; c) Cell viability of HeLa cell after treating with $200 \mu\text{g mL}^{-1}$ of drug; d) AO/EB stained fluorescence images of HeLa cells after treatment of 1,3 and 5 days respectively; e) Cell viability of B16-F10 cells after treatment with $200 \mu\text{g mL}^{-1}$ 142

Figure 6.8: a) Images of mice at initial day and after treatment with D-P-L-MC-D, pure drug and Gel-D indicated systems for varying time interval ; b) Relative changes in tumor volume with time treated with indicated Gels ; c) Relative changes in body weight with time treated with indicated systems; d) Kaplan Meir curve showing the survival rate of mice treated with different systems; e) Plasma drug concentration versus time profile for pure drug and D-P-L-MC-D treated albino mice after intravenous administration at 5 mg/kg body weight and an equivalent amount of drug in D-P-L-MC-D. 145

Figure 6.9: a) Histopathological images of vital organs after treatment; b) Biochemical parameters, Hepatic function test including AST, ALT, and ALP: c) Renal function namely

BUN and Creatinine of the mice treated with Gels. Corresponding values of healthy mice are indicated by the arrows; d) MIA stained tumor tissues of control, drug and D-P-L-MC-D..... 148

List of Table

Table 3.1: Release constant k , correlation coefficient (r), release exponent (n) calculated from various models for drug loaded CD and its respective copolymers.....	63
Table 4.1: Release constant k , correlation coefficient (r), release exponent (n) calculated from various models for short chain PU graft	93
Table 5.1: Release constant k , correlation coefficient (r), release exponent (n) calculated from various models for different generations of CD	109
Table 6.1: Release constant k , correlation coefficient (r), release exponent (n) calculated from various models for drug loaded dextrin and its respective copolymers.....	136

List of Schemes

Scheme 2.1: Chemical scheme showing grafting of polyurethane onto CD.....	36
Scheme 2.2: Chemical scheme showing grafting of short polyurethane chains onto CD. .	37
Scheme 2.3: Scheme showing formation of different generations of CD using small spacer HMDI and its subsequent grafting with polyurethane.....	39
Scheme 2.4: Chemical scheme showing grafting of polyurethane onto linear biopolymer dextrin.....	40

Abbreviations

CRS	Control release systems
3D	Three dimensional
PEG	Poly ethylene glycol
PTX	Paclitaxel
DOX	Doxorubicin
i.v	Intravenous
HEMA	Hydroxyl ethyl-meth acrylate
MBA	N,N'-methylene bis(acrylamide)
HA	Hyaluronan
CD	Cyclodextrin
CPT	Camptothecin
ATRP	Atom transfer radical polymerisation
RAFT	Reversible addition fragmentation transfer
CMC	Carboxymethyl cellulose
HEC	Hydroxyl ethyl cellulose
HCPT	Hydroxycamptothecin
TP	Tea polyphenols
G	Guanine
C	Cytosine
h	Hour
t	Time
T	Temperature

$^{\circ}\text{C}$ Degree Celcius

σ Stress

ε Strain